IDDI & Roche Identify DFS As Way Forward In Early Breast Cancer

Article

Applied Clinical Trials

Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.  

To learn more about their findings, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.